Pharmacyclics upgraded to Buy from Neutral at Goldman Goldman upgraded Pharmacyclics ahead of the launch of lead drug ibrutinib. The firm raised its peak sales estimate to $7.5B from $5.7B in 2024 given the large pool of CLL patients in need of treatment, launch timelines that are earlier than expected, and increased competitive visibility. The firm raised its price target to $170 from $111 and views Pharmacyclics as an attractive takeover target.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.